Tuberculosis cost-effectiveness of therapy

Jump to navigation Jump to search

Tuberculosis Microchapters


Patient Information


Historical Perspective




Differentiating Tuberculosis from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


HIV Coinfection


History and Symptoms

Physical Examination

Laboratory Findings


Chest X Ray



Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies


Medical Therapy

Special Conditions


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Tuberculosis cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Tuberculosis cost-effectiveness of therapy

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Tuberculosis cost-effectiveness of therapy

CDC on Tuberculosis cost-effectiveness of therapy

Tuberculosis cost-effectiveness of therapy in the news

Blogs on Tuberculosis cost-effectiveness of therapy

Directions to Hospitals Treating Tuberculosis

Risk calculators and risk factors for Tuberculosis cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Mashal Awais, M.D.[2]; Ammu Susheela, M.D. [3]


Tuberculosis treatment must be evaluated for relative cost-effectiveness of inpatient and outpatient models of care as it will benefit regions where tuberculosis is endemic. It is highly recommended to treat the TB patient in ambulatory care instead of inpatient setting unless there are severe complications.[1]

Cost effectiveness of therapy

While measurements of morbidity and mortality are important considerations for estimating the burden of disease in populations, they give an incomplete picture of the adverse effect of sickness on human welfare especially the economic consequences of poor health that may be substantial.

Analysis of the economic effect of the disease addresses multiple policy questions regarding the results of disease. Some of these questions are associated with the microeconomic level of households, firms, or government – such as the effect of the disease on a household’s income or a firm’s profits – while others relate to the macroeconomic level, including the cumulative effect of a disease on a country’s currency and future gross domestic product (GDP).

WHO suggests a outlined conceptual framework within which the economic burden of diseases and injuries can be appropriately estimated. [2]

The cost of the current regimen is approximately 4000 US$ per patient excluding laboratory, human resource, and patient opportunity costs. [3]

The cost-effectiveness in various tubercular control interventions in Africa region is given below. [3]

Intervention Yearly costs with 95% coverage level
Minimal DOTS 366.3 million $
Full DOTS 612.2 million $
Minimal DOTS with resistant cases 495.9 million $
Full combination 739.4 million $


  1. Fitzpatrick C, Floyd K (2012). "A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis". Pharmacoeconomics. 30 (1): 63–80. doi:10.2165/11595340-000000000-00000. PMID 22070215.
  2. "Cost-effectiveness and strategic planning".
  3. 3.0 3.1 "Cost effectiveness purposed by WHO".

Template:WH Template:WS